Nano Dimension (TASE:NNDM,NASDAQ:NNDM), announced today that its wholly owned subsidiary, Nano Dimension Technologies Ltd., has filed a patent application with the U.S. Patent and Trademark Office for the development of three-dimensional (3D) inkjet printing of bio-artificial multi-layered complex structures composed of cells, extracellular matrices, supportive components and stable and fugitive inks.
The patent application primarily refers to 3D bio-printing of nephron-like functioning structures that are designated to filter whole blood flow. The patent application presents a novel concept for 3D bio-printing of complex functioning structures that mimic the blood filtration process in the kidney’s nephron. The company believes that the covered technology could lead to functioning multi-nephron kidney-like structures for organ transplant, with clear industrial and medical applicability, and significant commercial potential. Also, the covered technology has potential as an effective model for drug development research and toxicology.
About Nano Dimension Ltd.
Nano Dimension, founded in 2012, focuses on development of advanced 3D printed electronics systems and advanced additive manufacturing. Nano Dimension’s unique products combine three advanced technologies: 3D inkjet, 3D software, and nanomaterials. The company’s primary products include the first 3D printer dedicated to printing multi-layer PCBs (printed circuit boards), and advanced nanotechnology-based conductive and dielectric inks.
In addition to the trading of the company’s American Depositary Shares on NASDAQ, the company’s ordinary shares are also traded on the TASE in Israel. The Bank of New York Mellon serves as the depositary for Nano Dimension.
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward looking statements in this press release when we discuss the potential and possible uses of our products, the company’s belief that the covered technology could lead to functioning multi-nephron kidney-like structures for organ transplant, with clear industrial and medical applicability, and significant commercial potential and that the covered technology has potential as an effective model for drug development research and toxicology. Because such statements deal with future events and are based on Nano Dimension’s current expectations, they are subject to various risks and uncertainties. Actual results, performance or achievements of Nano Dimension could differ materially from those described in or implied by the statements in this press release.
In addition, we cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to us. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Nano Dimension’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 7, 2017, and in any subsequent filings with the SEC. Except as otherwise required by law, Nano Dimension undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events